10% is a big deal but there are many different ways to persue better health outcomes and if we overrate particular approaches and underfund others that can be a problem.
At the moment we have 35 vaccine candiates in clinical evaluation for COVID-19 while on the other hand we have trouble spending 20 million to have decent studies on whether the top 8 most promissing antivirals helps with COVID-19.
10% is a big deal but there are many different ways to persue better health outcomes and if we overrate particular approaches and underfund others that can be a problem.
At the moment we have 35 vaccine candiates in clinical evaluation for COVID-19 while on the other hand we have trouble spending 20 million to have decent studies on whether the top 8 most promissing antivirals helps with COVID-19.